Andrew Dickinson

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

Kendall Dickinson & Koenig LLC provides legal services. The private company is based in Denver, CO.

Sutter Health engages in the provision of healthcare services. It offers allergy care, asthma care, gastroenterology, imaging, liver care, occupational health, pediatric, bioethics, dermatology, emergency, back and spine, heart and vascular, cancer, and fertility services. The company was founded in January 1996 and is headquartered in Sacramento, CA.

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.